121 related articles for article (PubMed ID: 1501121)
1. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.
Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC
J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
[TBL] [Abstract][Full Text] [Related]
3. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
Germonpré PR; Joos GF; Pauwels RA
Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
[TBL] [Abstract][Full Text] [Related]
4. Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.
Rinaldi-Carmona M; Congy C; Simiand J; Oury-Donat F; Soubrie P; Breliere JC; Le Fur G
Mol Pharmacol; 1993 Jan; 43(1):84-9. PubMed ID: 8423772
[TBL] [Abstract][Full Text] [Related]
5. Regulation of 5-hydroxytryptamine2 (5-HT2) receptor expression in cultured rat aortic smooth muscle cells by SR 46349B, a selective 5-HT2 receptor antagonist.
Rinaldi-Carmona M; Prabonnaud V; Bouaboula M; Poinot-Chazel C; Casellas P; Le Fur G; Herbert JM
J Biol Chem; 1994 Jan; 269(1):396-401. PubMed ID: 8276825
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.
Rinaldi-Carmona M; Bouaboula M; Congy C; Oury-Donat F; Simiand J; Shire D; Casellas P; Soubrié P; Brelière JC; Le Fur G
Eur J Pharmacol; 1993 Jun; 246(1):73-80. PubMed ID: 8354344
[TBL] [Abstract][Full Text] [Related]
7. Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Congy C; Pointeau P; Vidal H; Brelière JC; Le Fur G
Life Sci; 1994; 54(2):119-27. PubMed ID: 8277817
[TBL] [Abstract][Full Text] [Related]
8. Further evidence that various 5-HT receptor subtypes modulate central respiratory activity: in vitro studies with SR 46349B.
Monteau R; Di Pasquale E; Hilaire G
Eur J Pharmacol; 1994 Jun; 259(1):71-4. PubMed ID: 7957597
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of a new 5-hydroxytryptamine2 receptor antagonist, DV-7028.
Shibano T; Tanaka T; Morishima Y; Yasuoka M; Watanabe K; Fujii F
Arch Int Pharmacodyn Ther; 1992; 319():114-28. PubMed ID: 1285670
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
[TBL] [Abstract][Full Text] [Related]
11. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.
Dumuis A; Bouhelal R; Sebben M; Cory R; Bockaert J
Mol Pharmacol; 1988 Dec; 34(6):880-7. PubMed ID: 2849052
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
13. Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle.
Cohen ML; Schenck KW; Colbert W; Wittenauer L
J Pharmacol Exp Ther; 1985 Mar; 232(3):770-4. PubMed ID: 3973826
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
Hamel E; Robert JP; Young AR; MacKenzie ET
J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950
[TBL] [Abstract][Full Text] [Related]
15. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
Millan MJ; Bervoets K; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different arterial tissues suggests possible 5-hydroxytryptamine2 receptor heterogeneity.
Killam AL; Nikam SS; Lambert GM; Martin AR; Nelson DL
J Pharmacol Exp Ther; 1990 Mar; 252(3):1083-9. PubMed ID: 2319460
[TBL] [Abstract][Full Text] [Related]
17. Effect of 5-hydroxytryptamine3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices.
Edwards E; Harkins K; Ashby CR; Wang RY
J Pharmacol Exp Ther; 1991 Mar; 256(3):1025-32. PubMed ID: 1848625
[TBL] [Abstract][Full Text] [Related]
18. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
Cushing DJ; Cohen ML
J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
[TBL] [Abstract][Full Text] [Related]
19. McN-5652: a highly potent inhibitor of serotonin uptake.
Shank RP; Vaught JL; Pelley KA; Setler PE; McComsey DF; Maryanoff BE
J Pharmacol Exp Ther; 1988 Dec; 247(3):1032-8. PubMed ID: 2905001
[TBL] [Abstract][Full Text] [Related]
20. Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors.
Cohen ML; Colbert WE
J Pharmacol Exp Ther; 1986 Jun; 237(3):713-8. PubMed ID: 3712277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
